Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bioventix Plc | BVXP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3,750.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3,750.00 | 3,750.00 | 3,750.00 | 3,750.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 23/10/2024 07:26 by carcosa Well worth a read for any investor that likes detail, the latest from Maynard Payton. |
Posted at 12/2/2024 12:16 by maddox A Director's sale, if well handled, can work to enhance the share price - you sell sufficient shares to entice in a new Financial Investor - but not sell them as big a holding as they which to have. They then need to buy in the open market, creating demand and supporting the share price whilst they accumulate their desired holding.Can't say whether this is the case here but looks likely. |
Posted at 29/1/2024 15:58 by jurgenklopp Peter Harrison has sold £2.6 million worth of shares to a new institutional investor. |
Posted at 31/10/2023 11:54 by stepone68 Hi alter ego, I will definitely email investor relations, but would also like input from here if possible.LevR - I read all that. What am asking is, why will payments cease in 2032. I realise the contract runs out then, but contracts are renewed or extended all the time. Why do they say in the results 'payments will cease' in 2032. There must be more to it than that. Thanks StepOne |
Posted at 25/5/2023 11:52 by melloteam Just to let shareholders and prospective investors know that the CEO of Bioventix will be interviewed on our Mello2023 webinar, which begins at 1pm today. The programme for the evening is as follows: 1.00 pm A nostalgic interview with David Hornsby, ex Ideagen 1.30 pm Company presentation by Wise Alpha 2.00 pm Company presentation by Belvoir Group PLC 2.30 pm David Stredder interviews another Mello hero, Peter Harrison, CEO Bioventix 3.00 pm Company presentation by Frenkel Topping Group 3.30 pm Company presentation by Fintel plc 4.00 pm Gervais Williams presents ‘How can it be that UK-quoted microcaps might be one of the prime beneficiaries of the retreat of globalisation?&rsquo There will be over 500 investors attending and these are very popular shows with company presentations, fund manager and investor interviews, and panel sessions. Tickets are £25 and still available. Use code ME23Virtual for 70% off! |
Posted at 28/3/2023 10:25 by igbertsponk "we are pleased to see a solid performance of our core business and look forward to this continuing over the remainder of the year"That's pretty bullish for the traditionally VERY conservative BVXP. On the Alzheimers test "the outlook remains exciting" is also pretty bullish. I'm happy to remain invested and may well add on any dips. This company has never let us investors down. They signal when things won't be super and usually outperform. And the Board are bargain prices. I was pleased to see them take some reward off the table recently selling some shares. |
Posted at 11/11/2021 15:44 by gnnmartin I hoped to find the latest BVXP presentation to investors, but I can't find anything later that 2019. I expected to find it on the BVXP web site, but that gives surprisingly little information.Can anyone tell me where I can find what I seek? |
Posted at 19/10/2021 09:54 by vprt The main thing that has stopped me from buying is that Troponin is the big growth hope, but it is not owned and permanent, it is just a contract - admittedly a very long contract (2031, if memory serves?) but as a long term investor I don't like that the expiry (a big cliff edge if Troponin is successful) will loom larger and larger over time.I love management's frankness about rabbit and synthetics, but long term these threats also add to my unease about paying a big multiple today. (But will keep watching) |
Posted at 10/12/2020 00:59 by davidosh Just to mention that the Xmas special MelloMonday BASH may feature Bioventix on the 14th December and I think shareholders and potential investors will appreciate the analysis. There is also an interview with Keith Ashworth Lord who is a highly respected fund manager and well worth listening to. Keith's fund Castlefield are of course one of the largest shareholders in Bioventix.The Mello Monday event starts at 6pm The full programme is available on the website. In the MelloBASH... The analysts, fund manager and well known investors on the panel will give their honest verdicts on whether four/five companies are a Buy Avoid Sell or Hold at this current juncture in the markets. All investors welcome and if you use the code MMTADVFN50 you will get a half price ticket. Great investor content and entertainment. We had nearly 400 investors attend last month so these are very popular. |
Posted at 12/10/2020 13:34 by davidosh Just to confirm that Peter Harrison will be doing a 30 minute presentation with Q&A at the next MelloMondayThe Mello Monday event starts at 6pm and lasts until 9.30pm. There are nine sessions and the events are attended by 300 plus investors. The full amended programme to include this Bioventix presentation will be available on the website later today but provisionally Peter is expected to start at 6.30pm. A very popular final session of each event is the MelloBASH... The analysts, fund manager and well known investors on the panel will give their honest verdicts on whether four companies are a Buy Avoid Sell or Hold at this current juncture in the markets. All investors welcome and if you use the code MMV5 you will get a half price introductory ticket. It is quality investor content and entertainment. We had 329 investors attend last month so these are very popular. Annual passes are available and certainly a very low cost way of watching the 18 scheduled for the coming year as you will also be sent a link to the recordings to watch at your leisure and receive discounts for other investor services such as Stockopedia, ShareSoc Masterclasses etc. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
